HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA...

Area of Science:

• Ophthalmology
• Oncology
• Pharmacology

Background:

• Retinoblastoma (RB) is the most common intraocular malignancy in children.
• Refractory and recurrent intraocular RB poses significant treatment challenges.
• Intravitreal chemotherapy offers a localized treatment approach for intraocular tumors.

Purpose of the Study:

• To evaluate the outcomes and safety of intravitreal topotecan 100 mcg/0.1cc (IVitT100) as monotherapy.
• To assess IVitT100 efficacy in treating refractory or recurrent intraocular retinoblastoma.

Main Methods:

• Retrospective single-center study involving 7 RB patients.
• Patients received IVitT100 monotherapy with a minimum 3-month follow-up.
• Disease classification based on the International Classification of Retinoblastoma.

Main Results:

• Tumor control was achieved in 71% (5 of 7) of eyes with IVitT100 monotherapy.
• 100% tumor control was observed for vitreous, epiretinal, and subretinal seeds.
• Globe salvage was achieved in all treated eyes (100%).
• Electroretinogram showed no significant baseline changes.

Conclusions:

• Intravitreal topotecan (IVitT100) is a safe treatment option for refractory/recurrent intraocular RB.
• IVitT100 demonstrates significant promise in controlling refractory vitreous seeds, subretinal seeds, and intraretinal tumors.
• Further investigation into IVitT100 as a monotherapy for intraocular RB is warranted.